Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...

If you're a new investor and tend to gravitate toward growth stocks, there are plenty of compelling buys to consider in the ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Q3 2025 Earnings Call November 12, 2025 8:00 AM ESTCompany ParticipantsJessie Yeung - Vice President of Finance, ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an update. Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of ...

Discussing the company’s robust growth trajectory for its CARVYKTI therapy, he pointed toward the therapy’s rising clinical ...